MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Bayer AG

Suletud

SektorRahandus

26.36 -0.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.305

Max

26.415

Põhinäitajad

By Trading Economics

Sissetulek

1.6B

1.3B

Müük

2B

14B

P/E

Sektori keskmine

30.9

24.968

Aktsiakasum

2.49

Dividenditootlus

0.44

Kasumimarginaal

9.492

Töötajad

90,885

EBITDA

1.9B

3.6B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+0.53% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.44%

4.18%

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

3.5B

25B

Eelmine avamishind

26.53

Eelmine sulgemishind

26.36

Uudiste sentiment

By Acuity

37%

63%

139 / 538 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Bayer AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2025, 08:22 UTC

Tulu
Suurimad hinnamuutused turgudel

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13. mai 2025, 06:09 UTC

Tulu

Bayer Confirms Guidance Despite Net Profit Drop

24. märts 2025, 09:37 UTC

Suurimad hinnamuutused turgudel

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5. juuni 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30. mai 2025, 13:47 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27. mai 2025, 12:22 UTC

Market Talk
Tulu

Bayer's Prospects Are Improving -- Market Talk

16. mai 2025, 13:42 UTC

Kuumad aktsiad

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16. mai 2025, 08:57 UTC

Kuumad aktsiad

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15. mai 2025, 22:46 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13. mai 2025, 06:50 UTC

Market Talk
Tulu

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13. mai 2025, 05:36 UTC

Tulu

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13. mai 2025, 05:35 UTC

Tulu

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13. mai 2025, 05:34 UTC

Tulu

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13. mai 2025, 05:34 UTC

Tulu

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13. mai 2025, 05:32 UTC

Tulu

Bayer 1Q EPS EUR2.49

13. mai 2025, 05:32 UTC

Tulu

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13. mai 2025, 05:32 UTC

Tulu

Bayer 1Q Ebitda Before Special Items EUR4.085B

13. mai 2025, 05:31 UTC

Tulu

Bayer 1Q EBIT EUR2.32B

13. mai 2025, 05:31 UTC

Tulu

Bayer 1Q Net Pft EUR1.30B

13. mai 2025, 05:31 UTC

Tulu

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13. mai 2025, 05:30 UTC

Tulu

Analysts Saw Bayer 1Q Sales at EUR13.41B

13. mai 2025, 05:30 UTC

Tulu

Bayer 1Q Sales EUR13.74B

13. mai 2025, 05:30 UTC

Tulu

Bayer Backs 2025 View

14. apr 2025, 13:00 UTC

Peamised uudised

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7. apr 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2. apr 2025, 09:27 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10. märts 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Bayer AG Prognoos

Hinnasiht

By TipRanks

0.53% tõus

12 kuu keskmine prognoos

Keskmine 26.58 EUR  0.53%

Kõrge 33 EUR

Madal 20 EUR

Põhineb 13 Wall Streeti analüütiku instrumendi Bayer AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

13 ratings

3

Osta

10

Hoia

0

Müü

Tehniline skoor

By Trading Central

22.99 / 23.88Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

139 / 538 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.